Grant: Master's Award: Canada Graduate Scholarships
University of Toronto
$17,500.00
Investigating the genetic background of rapid eye movement (REM)-sleep behaviour disorder to predict alpha-synucleinopathies
EF 2020-21
Résumé
Parkinson's disease, dementia with Lewy bodies, and multiple systems atrophy are collectively known as αlpha-synucleinopathies, which are characterized by aggregation and accumulation of αlpha-synuclein. Neurodegeneration at the time of diagnosis is irreversible, resulting in poor prognosis and failed outcomes in clinical trials. The majority individuals with rapid-eye-movement (REM)-sleep behaviour disorder (RBD) later develop alpha-synucleinopathies, providing potential for an earlier diagnosis. Advances in genomic approaches such as high-throughput sequencing have grown rapidly over the last few decades, and allow for a cost-effective and comprehensive investigation of the underlying genetic background in disease phenotypes. This research proposal offers the use of these tools to investigate the genetic background of RBD and its overlap with the genetic backgrounds of αlpha-synucleinopathies. Gene-based burden analyses will be conducted on whole genome sequencing (WGS) data from patients and controls to investigate the accumulation of rare variants in one of the cohorts compared to the others. Genes with the most accumulation of variants will then be sequenced in additional RBD samples and controls. Copy number variant analyses on WGS data cohorts will be performed, followed by association and regression tests to assess whether the variants are associated with increased or reduced risks of developing RBD and the three αlpha-synucleinopathies. The identification of candidate genes and their variants in RBD and αlpha-synucleinopathies will facilitate understanding of the mechanisms and genetic background underlying these neurodegenerative diseases, potentially allowing for earlier diagnoses and improved clinical trial outcomes for neuroprotective therapies.
Programme
Master's Award: Canada Graduate Scholarships
Bénéficiaire
Emplacement
Ontario, Canada
Type de bénéficiaire
Academia
Type
Grant
Source
CIHR Funding Decisions Database
Tel que publié
Id
449587
Name
Rahmanian Shahrzad
Region
Ontario
Country
Canada
Orgtype
Institution Paid; Research Institution
Prcname2
Special Cases - Awards Programs
Projecttitle
Investigating the genetic background of rapid eye movement (REM)-sleep behaviour disorder to predict alpha-synucleinopathies
Programtype2
Studentship Programs
Orgnameinp2
University of Toronto
Cihramount2
$17,500
Cihrequipment2
$0
Programname2
Master's Award: Canada Graduate Scholarships
Keyworddelim
Alpha-Synucleinopathies; Computational Genomics; Genetic Variants; High-Throughput Sequencing; Neurodegeneration; Rem-Sleep Behaviour Disorder; Whole Genome Sequencing
Abstract
Parkinson's disease, dementia with Lewy bodies, and multiple systems atrophy are collectively known as αlpha-synucleinopathies, which are characterized by aggregation and accumulation of αlpha-synuclein. Neurodegeneration at the time of diagnosis is irreversible, resulting in poor prognosis and failed outcomes in clinical trials. The majority individuals with rapid-eye-movement (REM)-sleep behaviour disorder (RBD) later develop alpha-synucleinopathies, providing potential for an earlier diagnosis. Advances in genomic approaches such as high-throughput sequencing have grown rapidly over the last few decades, and allow for a cost-effective and comprehensive investigation of the underlying genetic background in disease phenotypes. This research proposal offers the use of these tools to investigate the genetic background of RBD and its overlap with the genetic backgrounds of αlpha-synucleinopathies. Gene-based burden analyses will be conducted on whole genome sequencing (WGS) data from patients and controls to investigate the accumulation of rare variants in one of the cohorts compared to the others. Genes with the most accumulation of variants will then be sequenced in additional RBD samples and controls. Copy number variant analyses on WGS data cohorts will be performed, followed by association and regression tests to assess whether the variants are associated with increased or reduced risks of developing RBD and the three αlpha-synucleinopathies. The identification of candidate genes and their variants in RBD and αlpha-synucleinopathies will facilitate understanding of the mechanisms and genetic background underlying these neurodegenerative diseases, potentially allowing for earlier diagnoses and improved clinical trial outcomes for neuroprotective therapies.
Competitiondate
202012
Approvedterm2
1 yr 0 mth
Pinamesdelim
Rahmanian, Shahrzad
Approvedterm
1 an 0 mois
Cihrcontribution2
~ $17,500~ $0~